Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing natalizumab (medicinal product) | Is a | Product containing alpha-4 integrin receptor antagonist (product) | true | Inferred relationship | Some | ||
| Product containing natalizumab (medicinal product) | Is a | Product containing monoclonal antibody (product) | true | Inferred relationship | Some | ||
| Product containing natalizumab (medicinal product) | Has active ingredient | Natalizumab (substance) | true | Inferred relationship | Some | 1 | |
| Product containing natalizumab (medicinal product) | Is a | Inflammatory bowel disease drug | false | Inferred relationship | Some | ||
| Product containing natalizumab (medicinal product) | Is a | Product containing murine-human monoclonal immunoglobulin G antibody | false | Inferred relationship | Some | ||
| Product containing natalizumab (medicinal product) | Is a | Product containing immunomodulator (product) | true | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
| Natalizumab 300mg injection solution 15mL vial | Is a | False | Product containing natalizumab (medicinal product) | Inferred relationship | Some | |
| Product containing precisely natalizumab 300 milligram/15 milliliter conventional release solution for injection vial | Is a | False | Product containing natalizumab (medicinal product) | Inferred relationship | Some | |
| Natalizumab-containing product in parenteral dose form | Is a | True | Product containing natalizumab (medicinal product) | Inferred relationship | Some | |
| Product containing only natalizumab (medicinal product) | Is a | True | Product containing natalizumab (medicinal product) | Inferred relationship | Some |
This concept is not in any reference sets